These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 20132874)

  • 1. Proton pump inhibitor administration via nasogastric tube in pediatric practice: comparative analysis with protocol optimization.
    Ponrouch MP; Sautou-Miranda V; Boyer A; Bourdeaux D; Montagner A; Chopineau J
    Int J Pharm; 2010 May; 390(2):160-4. PubMed ID: 20132874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel option in proton pump inhibitor dosing: lansoprazole orally disintegrating tablet dispersed in water and administered via nasogastric tube.
    Freston JW; Kukulka MJ; Lloyd E; Lee C
    Aliment Pharmacol Ther; 2004 Aug; 20(4):407-11. PubMed ID: 15298634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative study and optimisation of the administration mode of three proton pump inhibitors by nasogastric tube.
    Messaouik D; Sautou-Miranda V; Bagel-Boithias S; Chopineau J
    Int J Pharm; 2005 Aug; 299(1-2):65-72. PubMed ID: 15990258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stability of partial doses of omeprazole-sodium bicarbonate oral suspension.
    Johnson CE; Cober MP; Ludwig JL
    Ann Pharmacother; 2007 Dec; 41(12):1954-61. PubMed ID: 17956960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An in vitro comparison of different providers to deliver four proton pump inhibitor products through a feeding tube.
    Devlin JW; Bakshi A; Bungay K; Olsen KM
    Aliment Pharmacol Ther; 2006 Dec; 24(11-12):1603-11. PubMed ID: 17206948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel option for dosing of proton pump inhibitors: dispersion of lansoprazole orally disintegrating tablet in water via oral syringe.
    Gremse DA; Donnelly JR; Kukulka MJ; Lloyd E; Lee C
    Aliment Pharmacol Ther; 2004 Jun; 19(11):1211-5. PubMed ID: 15153174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of carbamazepine suspension through nasogastric feeding tubes.
    Clark-Schmidt AL; Garnett WR; Lowe DR; Karnes HT
    Am J Hosp Pharm; 1990 Sep; 47(9):2034-7. PubMed ID: 2121028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lansoprazole fast disintegrating tablet: a new formulation for an established proton pump inhibitor.
    Baldi F; Malfertheiner P
    Digestion; 2003; 67(1-2):1-5. PubMed ID: 12743433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro Approaches to Support Bioequivalence and Substitutability of Generic Proton Pump Inhibitors via Nasogastric Tube Administration.
    Ren P; Cui M; Anand O; Xia L; Zhao ZJ; Sun D; Sharp T; Conner DP; Peters J; Jiang W; Stier E; Jiang X
    AAPS J; 2017 Nov; 19(6):1593-1599. PubMed ID: 28879628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delivery of esomeprazole magnesium through nasogastric and gastrostomy tubes using an oral liquid vehicle as a suspending agent in vitro.
    Shah SA; Sander S; Coleman CI; White CM
    Am J Health Syst Pharm; 2006 Oct; 63(19):1882-7. PubMed ID: 16990636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of four lansoprazole dose levels and one dosage regimen of omeprazole on 24-hour intragastric pH in healthy subjects.
    Timmer W; Ripke H; Kleist P; Ehrlich A; Wieckhorst G; Lücker PW; Fuder H
    Methods Find Exp Clin Pharmacol; 1995 Sep; 17(7):489-95. PubMed ID: 8577212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of antisecretory treatment with proton pump inhibitors on serum pepsinogen I levels.
    Di Mario F; Ingegnoli A; Altavilla N; Cavallaro LG; Bertolini S; Merli R; Cavestro GM; Iori V; Maino M; Leandro G; Franzè A
    Fundam Clin Pharmacol; 2005 Aug; 19(4):497-501. PubMed ID: 16011738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative method for administering proton-pump inhibitors through nasogastric tubes.
    Peckman HJ
    Am J Health Syst Pharm; 1999 May; 56(10):1020. PubMed ID: 10365730
    [No Abstract]   [Full Text] [Related]  

  • 14.
    Hoover A; Chitranshi P; Momot M; Tyner K; Wokovich A
    Pharm Dev Technol; 2021 Oct; 26(8):846-851. PubMed ID: 34182865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of proton pump inhibitors in infantile gastroesophageal reflux disease.
    Higginbotham TW
    Ann Pharmacother; 2010 Mar; 44(3):572-6. PubMed ID: 20124466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proton pump inhibitor and clopidogrel interaction: fact or fiction?
    Laine L; Hennekens C
    Am J Gastroenterol; 2010 Jan; 105(1):34-41. PubMed ID: 19904241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Esomeprazole: a safe alternative to lansoprazole allergy?
    Kara M; Tanoglu A; Kutlu A; Sirkeci O; Kekilli M
    Iran J Allergy Asthma Immunol; 2014 Aug; 13(4):296-7. PubMed ID: 24659167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lessons from two cases of anaphylaxis to proton pump inhibitors.
    Choi SW; Han JM; Bae YJ; Lee YS; Cho YS; Moon HB; Kim TB
    J Clin Pharm Ther; 2012 Oct; 37(5):614-6. PubMed ID: 22642701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro evaluation of nasogastric administration methods for phenytoin.
    Cacek AT; DeVito JM; Koonce JR
    Am J Hosp Pharm; 1986 Mar; 43(3):689-92. PubMed ID: 3706323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delayed elimination of methotrexate associated with co-administration of proton pump inhibitors.
    Santucci R; Levêque D; Lescoute A; Kemmel V; Herbrecht R
    Anticancer Res; 2010 Sep; 30(9):3807-10. PubMed ID: 20944174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.